Cell Cure Neurosciences’ development pipeline is currently in the preclinical stage. Present objectives for development of OpRegen® include:
- Further evaluation of OpRegen® in vitro
- Demonstration of safety and efficacy in an animal model
- Generation of clinical grade cells for clinical trials
Buoyed by a recent $7.1 million equity investment by Cell Cure’s shareholders, the company will also continue its development work on neural progenitor cellular therapies intended for use in Parkinson’s disease and multiple sclerosis in parallel with the OpRegen® program.